Evidence map›Paper›PMID 32571767›Full record

ArticleDisease models & mechanisms2020

A lineage-tracing tool to map the fate of hypoxic tumour cells.

Jenny A F Vermeer, Jonathan Ient, Bostjan Markelc, Jakob Kaeppler, Lydie M O Barbeau, Arjan J Groot, Ruth J Muschel, Marc A Vooijs

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. A novel lineage-tracing tool reveals that hypoxic tumor cells drive tumor relapse after radiotherapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Jenny A F VermeerDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-6772-9144
Jonathan IentDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-1251-1938
Bostjan MarkelcDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Jakob KaepplerDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Lydie M O BarbeauDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands.
Arjan J GrootDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands.
Ruth J MuschelDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK marc.vooijs@maastrichtuniversity.nl ruth.muschel@gmail.com.ORCID 0000-0002-5656-5970
Marc A VooijsDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands marc.vooijs@maastrichtuniversity.nl ruth.muschel@gmail.com.ORCID 0000-0003-1386-3027
Maastricht University Medical Centre · NLUniversity of Oxford · GBInstitute of Oncology Ljubljana · SI

Funding

Cancer Research UK C5255/A15935
6 · The paper itself

Abstract

Intratumoural hypoxia is a common characteristic of malignant treatment-resistant cancers. However, hypoxia-modification strategies for the clinic remain elusive. To date, little is known on the behaviour of individual hypoxic tumour cells in their microenvironment. To explore this issue in a spatial and temporally controlled manner, we developed a genetically encoded sensor by fusing the O

Indexed as

Biosensing TechniquesCell LineageCell TrackingSingle-Cell AnalysisTumor MicroenvironmentAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGenes, ReporterGreen Fluorescent ProteinsHeterograftsHumansHypoxia-Inducible Factor 1, alpha Subunitenhanced green fluorescent proteinGreen Fluorescent ProteinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitLuminescent ProteinsOxygenRecombinant ProteinsRed Fluorescent ProteinCre recombinaseHIFHypoxiaIntravital imagingLineage tracingNSCLC tumour

Identifiers

PMID32571767
PMCPMC7406318
OpenAlexW3036574932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.